Extended Data Fig. 4: Validation of the CD4-CreERT2+/−Eomesfl/fl mouse model.
From: CD4 T cells acquire Eomesodermin to modulate cellular senescence and aging
Splenocytes from either CD4-CreERT2+/−Eomesfl/fl mice (Eomes-KO; n = 5; age 3 months-old) or CD4-CreERT2−/−Eomesfl/fl mice (Control; n = 5) were isolated and analyzed for EOMES+ cells out of spleen-derived CD4 T cells with flow cytometry. In addition, spleen-derived T cells were activated using anti-CD3/anti-CD28 coated beads for 24 h and analyzed for cell survival and cytokine production with flow cytometry. a. Left: percentage of CD4 T cells (CD3+CD8−CD4+); Right: CD4 MFI. b. Left: percentage of live cells after activation; Right: percentage of CD4 T cells out of the live cells. c. Left: percentage of EOMES+ cells out of CD8 T cells; Right: quantitative analysis of EOMES MFI in CD8 T cells. d. Left: percentage of EOMES+ cells out of CD4 T cells; Middle: quantitative analysis of EOMES MFI in CD4 T cells; Right: a representative flow cytometry histogram plot illustrating the expression of EOMES in non-activated CD4 T cells (grey), activated Eomes-KO CD4 T cells (blue), or activated control CD4 T cells (orange). e. ELISA results of IFNγ (Left) and IL-2 (Right) in the supernatants of CD4 T cells derived from Control (n = 5) or Eomes-KO (n = 5) mice and activated for 24 h. Bars indicate mean ± SEM. Data were analyzed using a two-tailed Student’s t-test, unpaired, with exact P-values presented in the graphs.
